Pancreatic Cancer
-
healthPancreatic Cancer Pill Doubles Survival, Canada Trial Eyed
A daily pill, daraxonrasib, doubles survival for pancreatic cancer patients. Canadian doctors seek clinical trials.
-
healthNew Pancreatic Cancer Pill Shows Promise, 90% of Patients Respond in Early Trial
An experimental daily pill, daraxonrasib, shows a 90% disease control rate in advanced pancreatic cancer patients during early-stage clinical trials.
-
healthPan-RAS Inhibitor Shows Survival Gain in Pancreatic Cancer
Daraxonrasib, a pan-RAS inhibitor, demonstrated improved survival and tumor control in advanced pancreatic cancer in early trials.
-
healthExperimental Pancreatic Cancer Drug Daraxonrasib Nears Approval, Shows Surge in Demand
Daraxonrasib nearly doubles survival in trials, now in early access amid high demand before full FDA approval.
-
healthHope for Pancreatic Cancer Patients as New Drug Shows Promise
Revolution Medicines' daraxonrasib doubles survival in advanced pancreatic cancer, sparking patient demand and FDA compassionate use access.
-
healthTargeted Chemotherapy System Delivers Drugs Directly to Tumors, Sparing Healthy Cells
RenovoRx's TAMP platform delivers chemo directly to pancreatic tumors in a Phase III trial, improving quality of life and survival.
-
healthAI Model Spots Pancreatic Cancer 3 Years Earlier Than Doctors
A new AI model from Mayo Clinic analyzes subtle pancreatic tissue changes on CT scans to detect cancer up to three years before standard diagnosis.
-
healthNew AI Model Detects Pancreatic Cancer Years Before Diagnosis
REDMOD AI from Mayo Clinic and MD Anderson can spot pancreatic cancer up to 3 years early, catching 73% of cases vs 39% by specialists.